诺华司库奇尤单抗新适应症在华获批

Core Viewpoint - Novartis has received approval from the National Medical Products Administration for a new indication of secukinumab, which is now approved for treating adult patients with active radiographic axial spondyloarthritis (axSpA) who have inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) [1] Group 1: Drug Approval and Indications - Secukinumab is now approved for its sixth indication in China, following approvals for severe plaque psoriasis, ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa [1] - The newly approved indication targets axial spondyloarthritis (axSpA), a chronic inflammatory disease, specifically the early stage known as non-radiographic axial spondyloarthritis (nr-axSpA) [1] Group 2: Clinical Significance and Research - Patients with nr-axSpA typically start treatment with NSAIDs and physical therapy, but NSAIDs often only relieve symptoms without altering disease progression, leading to significant clinical and economic burdens due to delayed diagnosis [1] - Early diagnosis and treatment are crucial for improving clinical outcomes and reducing the burden on patients with nr-axSpA [1] - The PREVENT study, a global Phase III trial for secukinumab in nr-axSpA patients, demonstrated a higher ASAS40 response rate at week 16 compared to the placebo group, with improvements sustained until week 52 and good safety profile [1]